Dr. Lal Pathlabs Limited — Earnings Release 2023

Jul 28, 2022

==> picture [287 x 43] intentionally omitted <==

July 28, 2022

National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai -400 051 Mumbai- 400001

Subject: Press Release for unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2022

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2022

Thanking You,

Yours Faithfully,

For Dr. Lal Pathlabs Limited

==> picture [83 x 44] intentionally omitted <==

Rajat K ra Compan Secretary and Legal Head

Encl: As above

Classification: Internal

Regd. Office: Dr. Lal PathLabs Ltd .• Block E. Sector-18. Roh1n,. New Delhi - 110085, +91-11-30258600. Fax: +91-11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor. Tower B. SAS Tower. Medidty, Sector-38, Gurugram - 122 001. Haryana +91-124-30 J 6-500. Fax: +91-124-4234-468 E-mail: lalpath/abs@lalpathlabs.com. Web: www.lalpathlabs.com. CIN No.: L74899DLl995PLC065388

For Immediate Release

==> picture [159 x 37] intentionally omitted <==

July 28, 2022

Dr. Lal PathLabs Limited records revenue of Rs 503 Cr in Q1 FY 2022-23

New Delhi, India, July 28, 2022 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2022.

• Consolidated Performance Highlights: Q1 FY 2022-23 vs Q1 FY 2021-22 Non-Covid revenue up by 25% Covid revenue declined by 91% Normalised EBITDA at Rs 126 Cr with margin at 25% PBT at Rs 81 Cr with margin at 16%, and PAT Rs 58 Cr with margin at 12%

• Operating Revenue decreased by 17% in Q1 FY23 to Rs. 503 Cr vs Rs 607 Cr in Q1 FY22  Non-Covid Revenue increased by 25% in Q1 FY23 to Rs. 482 Cr vs Rs 386 Cr in Q1 FY22  Covid and Allied contributed 4% to Revenue in Q1 FY23, 36% in Q1 FY22  Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q1 FY21 is at Rs. 126 Cr (margins 25%) Vs Rs 199 Cr in the same quarter last year

• Normalised PBT* at Rs 94 Cr, margins 18.6% vs Rs 179 Cr. in Q1 last year

• Normalised PAT* at Rs 71 Cr, margins 14.0% vs Rs 134 Cr. in Q1 last year

• Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

==> picture [238 x 247] intentionally omitted <==

----- Start of picture text ----- Q1ParticularsFY23 FY22 Gr %Revenue 502.7 606.6 -17.1%Non Covid 481.8 385.7 24.9%Covid & Allied 20.9 220.9 -90.5%Expenditure 385.2 417.6 -7.8%EBITDA 117.5 189.0 -37.8%EBITDA Margins 23.4% 31.2%RSU & CSR cost 7.9 10.0Normalised EBITDA 125.5 199.0 -37.0%EBITDA Margins 25.0% 32.8%Net other Income/(Interest) -0.2 9.5Depreciation Cost 35.9 19.2PBT 81.4 179.3 -54.6%Margins 16.2% 29.6%PAT 58.2 133.7 -56.5%Margins 11.6% 22.0%EPS 7.0 15.9 -56.1%Normalised PBT* 93.7 179.3 -47.7%Margins 18.6% 29.6%Normalised PAT* 70.5 133.7 -47.3%Margins 14.0% 22.0%----- End of picture text -----

• *Normalised PBT and PAT are excluding notional depreciation of Rs.12.3 Cr on consolidation of Suburban.

Classification: Internal Dr. Lal Pathlabs Limited 12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

1

==> picture [159 x 37] intentionally omitted <==

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel Group Chief Financial Officer Dr. Lal PathLabs Limited

+91 124 3016500 cfo@lalpathlabs.com

Rakshit Tewari/Gargi Mukherjee Adfactors PR

+91 9935551036/+91 9650944756 rakshit.tewari@adfactorspr.com gargi.mukherjee@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Classification: Internal

Dr. Lal Pathlabs Limited

12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

2